Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

Circulation

Volumn 101, Issue 5, 2000, Pages 477-484

  Gotto Jr , Antonio M ^a   Whitney, Edwin ^b   Stein, Evan A ^c   Shapiro, Deborah R ^d   Clearfield, Michael ^e   Weis, Stephen ^e   Jou, Jesse Y ^a   Langendörfer, Alexandra ^d   Beere, Polly A ^d   Watson, Douglas J ^d   Downs, John R ^f   De Cani, John S ^g  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Heart and Vascular Institute of Texas   (United States)

^c Pharmaceutical Product Development   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^f WILFORD HALL MEDICAL CENTER   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apolipoproteins; Coronary disease; Lipids; Prevention; Risk factors

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN;

ADULT; AGED; AIR FORCE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SUDDEN DEATH; UNITED STATES; UNSTABLE ANGINA PECTORIS;

EID: 0342879940     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.5.477     Document Type: Article

References (20)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in participants with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339: 1349-1357.
5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
6. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323: 1289-1298.
7. Tall AR. An overview of reverse cholesterol transport. Eur Heart J. 1998;19(suppl A):A31-A35.
8. Downs JR, Beere PA, Whitney E, Clearfield M, Weis S, Rochen J, Stein EA, Shapiro DR, Langendorfer A, Gotto AM Jr. Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 1997;80:287-293.
9. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med. 1989;9:105-116.
10. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
11. Tukey J. Use of many covariates in clinical trials. Int Stat Rev. 1991;59:123-137.
12. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation. 1998;97:1436-1439.
13. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee D-J, Sherwin R, Shih J, Stamler J, Wentworth D. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial: Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992;152:1490-1500.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
15. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
16. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyorala K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ, for the Scandinavian Simvastatin Survival Study group. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1453-1460.
17. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998; 97:1440-1445.
18. Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, Despres J-P. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 1998;279:1955-1961.
19. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins: pathophysiology and new therapeutic approaches. Eur Heart J. 1998;19:A24-A30.
20. Marcovina SM, Gaur VP, Albers JJ. Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-I and B. Clin Chem. 1994;40: 574-578.